A Medical Device Daily
Stiefel Laboratories (Coral Gables, Florida), an independent pharmaceutical company specializing in dermatology, reported that it has acquired France-based ABR Invent and ABR Development, developers of the dermal filler Atlean.
Stiefel will acquire all shares of the companies through a stock purchase agreement.
Atlean is commercialized in France and Italy and distribution and manufacturing agreements for the product will remain in place throughout Europe.
All sales representatives formerly employed by ABR Development will now become employees of Stiefel, the company said.
Over the next 18 months, Stiefel plans to launch Atlean in multiple areas, including parts of Europe, Asia Pacific, Latin America and the Caribbean. The company said it will continue clinical development of Atlean in order to submit the product for approval from the FDA and other regulatory bodies around the world. The company said it also expects to develop other products from the ABR portfolio.
Atlean uses a combination of tricalcium phosphate particles suspended in a hyaluronic acid gel. The injectable product is recommended for sculpting and remodeling the face. It is implanted subcutaneously or intra-dermally.
USA Uranium (USAU; Las Vegas) reported that it has agreed to acquire all rights, title and interest to a collection of software and hardware products and technologies known as the MyScreenMD.com program for an undisclosed sum.
The MyScreenMD program is focused upon becoming the leading provider of Internet-based home medical diagnostic and testing products using a screen-based Internet access device in partnership with the medical community.
USAU said MyScreenMD's testing system and products offer a wide range of alternatives to those who could not otherwise obtain crucial testing and immediate evaluation of their medical condition.
In other dealmaking news: DNAstar (Madison, Wisconsin), a bioinformatics software company, and the Oklahoma Medical Research Foundation (OMRF; Oklahoma City) reported the signing of a broad site license agreement for the use of Lasergene sequence analysis software developed by DNAstar.
Lasergene will be available to an unlimited number of users at OMRF for a four-year time period.
Founded in 1946, OMRF is a non-profit medical research center focusing much of its efforts in the search for the causes and cures for heart disease, Alzheimer's and other brain diseases, cancer and diabetes.
Lasergene is sequence analysis software that provides users with tools for performing a wide range of assembly, visualization and analysis operations on data generated by conventional Sanger sequencing method as well as next-generation techniques.
The desktop software allows users to analyze samples ranging from small plasmids up to large bacterial genomes. It is designed to provide scientists with information on the molecular issues associated with genetic disorders.